Skip to content
The Nexus
HEALTHJul 28 · 10:00 UTCSTAT NEWSAdam Feuerstein

STAT+: Preliminary trial results suggest a path to a safer Alzheimer’s treatment

Preliminary clinical trial results for ProMIS Neurosciences' amyloid-targeting Alzheimer’s treatment showed 4.4% ARIA rates, all mild and asymptomatic, with no cases of severe brain swelling (ARIA-E). The drug demonstrated low brain bleeding (ARIA-H) and suggests potential safety advantages over approved treatments.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned
ProMIS NeurosciencesorganizationAlzheimer’s diseasetopicAriatopicARIA-EtopicARIA-Htopic
Spot something wrong with this article?Report a problem →
Forward this
Related Signal

Adjacent reporting

STAT+: Preliminary trial results suggest a path to a safer Alzheimer’s treatment · The Nexus